NASDAQ · DBVT

DBV Technologies S. A.

$13.63 -$0.23 (-1.66%) 1D After hours
Session Pulse Overnight session 1 mentions today No new SEC filings since Mon close its sector ranked 6/11 this week Full pulse →

Key Metrics

$820.28M
Market cap
P/E · TTM
$147.00K
Revenue · TTM
−$20.52M
Net income
EPS · TTM $-0.20
Dividend yield
Free cash flow
Beta · 1Y 1.05
EBITDA · TTM
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 27
    Offering paper hit the record (Form S-3).

    S-3ASR - DBV Technologies S.A. (0001613780) (Filer)

    RECEIPT: SEC FORM S-3, TIMESTAMPED
  • Jul 22
    From its Feb 10 high, the share price fell 43%.

    Peak close $23.80 on Feb 10; trough close $13.63 on Jul 22. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -43%
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jul 7
    The stock moved +11.1% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jul 7
  • Mar 11
    The stock moved -12.0% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Mar 11

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$820.28M
Enterprise value
Shares outstanding59.2M
52-wk range$8.51 – $26.19
Avg volume · 20D97.9K
Net cash
Book value / share$2.03
IndustryBiological Products, (No Diagnostic Substances)
ExchangeNASDAQ
About DBV Technologies S. A.
IPO dateOct 22, 2014
Employees170

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S5,580.11
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross
Operating -13,823.8%
Net -13,959.9%
FCF
ROE / ROIC -9.9% · —

Financial Health

Current ratio4.76
Quick ratio
Debt / equity
Debt / EBITDA
Net cash
Working capital$194.90M

Cash Flow · TTM

Operating CF
Capex
Free cash flow
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

0 / 9
Weak fundamentals · 0 of 9 signals passing

Altman Z-Score

6.7
Safe zone (> 2.99) · bankruptcy risk negligible

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings